Richard Schwartz

Delmar (Canada) — Canada

Computer Science · Physical Sciences

60h-index17.5kcitations344works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Speech Recognition and Synthesis(141), Natural Language Processing Techniques(98), Speech and Audio Processing(67), Topic Modeling(59), Music and Audio Processing(38)

Publications344 total

VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study
Discover Oncology·2025Open Access
CTNI-73. ASSESSMENT OF MOLECULAR ALTERATIONS IN NEWLY DIAGNOSED GBM MGMT-UNMETHYLATED PATIENTS TREATED WITH VAL-083
Neuro-Oncology·2024Open Access
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
npj Vaccines·2024· 18 citedOpen Access
CTNI-77. POST-PROGRESSION TREATMENT AFTER VAL-083 WITH RADIATION IN NEWLY DIAGNOSED GBM MGMT UNMETHYLATED PATIENTS
Neuro-Oncology·2023Open Access
CTNI-78. EVALUATION OF POST-PROGRESSION TREATMENTS AFTER VAL-083 IN RECURRENT AND NEWLY DIAGNOSED GBM MGMT-UNMETHYLATED PATIENTS
Neuro-Oncology·2023Open Access
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Nature Medicine·2022· 84 citedOpen Access
Phase 2 study of VAL-083 and radiotherapy in newly diagnosed MGMT-unmethylated GBM
WFNOS 2022 Abstract Book·2022Open Access
CTNI-21. PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Neuro-Oncology·2021Open Access
CTNI-26. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING
Neuro-Oncology·2021· 1 citedOpen Access
SYST-05. PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Neuro-Oncology Advances·2021· 1 citedOpen Access
Abstract CT172: Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM
Cancer Research·2021· 1 cited
Abstract CT238: Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting
Cancer Research·2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
The Lancet Respiratory Medicine·2021· 63 citedOpen Access
CTNI-76. PHASE 2 CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
Neuro-Oncology·2020Open Access
CTNI-72. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING
Neuro-Oncology·2020Open Access
Development of a High Yielding Bioprocess for a Pre-fusion RSV Subunit Vaccine
Journal of Biotechnology·2020· 7 cited
Abstract CT273: Phase 2 trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma
Cancer Research·2020
Abstract CT272: Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting
Cancer Research·2020· 1 cited
Abstract A19: A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC)
Clinical Cancer Research·2020
The 2019 BBN Cross-lingual Information Retrieval System.
2020· 4 cited
page 1 of 18Next →

Frequent Co-authors

J. Makhoul(11), Barney S. Graham(11), Julie E. Ledgerwood(11), John R. Mascola(10), Sarah H. Plummer(9), Ingelise J. Gordon(9), Richard A. Koup(9), LaSonji A. Holman(8), Cynthia S. Hendel(8), Robert T. Bailer(8), Galina V. Yamshchikov(8), Sandra Sitar(8), Michelle Conan-Cibotti(7), Jamie Saunders(7), John Makhoul(6), Emily E. Coates(6), Pamela Costner(6), Zonghui Hu(6), Nina M. Berkowitz(6), Grace Chen(6)